Gilenya Sales Data
|Rank 53||Current sales rank, all
Last updated: November 2013 (updated quarterly).
The following data shows Gilenya U.S. retail sales in Q3 2013 compared to previous quarters.
|Date Range||Sales Rank||Sales ($000)||Units (000)|
|Q3 2013||53 (1)||$262,083||0.49%||61||-1.61%|
|Q2 2013||52 (15)||$260,801||10.75%||62||10.71%|
|Q1 2013||67 (1)||$235,496||1.18%||56||-1.75%|
|Q4 2012||66 (4)||$232,746||5.17%||57||3.64%|
|Q3 2012||70 (17)||$221,299||21.19%||55||12.24%|
|Q2 2012||87 ()||$182,611||49|
* Units refer to the number of packages sold.
|October 4, 2013||Gilenya Reduces MS Relapse Rates|
|September 25, 2013||Novartis: Study Confirms Long-Term Efficacy of Gilenya|
|April 20, 2012||Novartis Updates US Label on Gilenya Following Discussions With the FDA|
|April 20, 2012||European Medicines Agency Gives New Advice to Better Manage Risk of Adverse Effects on the Heart With Gilenya|
|December 21, 2011||FDA Drug Safety Communication: Safety Review of a Reported Death after the First Dose of Multiple Sclerosis Drug Gilenya (fingolimod)|
|January 31, 2011||New Oral Drugs Hailed for Treating Multiple Sclerosis|
|September 22, 2010||FDA Approves Gilenya - 1st Oral Drug for MS Relapses|
|September 22, 2010||Gilenya Approved for Relapsing MS|